Number Of Products Approved By Food And Drug Administration

No definition available.

Name:	aqst_NumberOfProductsApprovedByFoodAndDrugAdministration
Namespace Prefix:	aqst_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Sale of Stock, Aggregate Offering Price

+ References

No definition available.

+ Details

Name:	aqst_SaleOfStockAggregateOfferingPrice
Namespace Prefix:	aqst_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Sale Of Stock, Remaining Amount Available For Offering

+ References

No definition available.

+ Details

Name:	aqst_SaleOfStockRemainingAmountAvailableForOffering
Namespace Prefix:	aqst_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585

+ Details

Name:	us-gaap_PaymentsOfStockIssuanceCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsidiarySaleOfStockLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=aqst_EquityDistributionAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=aqst_AtTheMarketOfferingAmendmentOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=aqst_AtTheMarketOfferingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Corporate Organization and Company Overview (Details)			1 Months Ended	6 Months Ended	7 Months Ended	8 Months Ended
Corporate Organization and Company Overview (Details)	Jun. 30, 2021 USD ($)	Mar. 26, 2021 USD ($)	Dec. 31, 2020 USD ($) shares	Jun. 30, 2021 USD ($) product shares	Jun. 30, 2021 USD ($) shares	Jun. 30, 2021 USD ($)
Subsidiary, Sale of Stock [Line Items]
Number of products approved by Food and Drug Administration \| product				5
Equity Distribution Agreement
Subsidiary, Sale of Stock [Line Items]
Sale of stock, aggregate offering price			$ 25,000
Number of shares issued in transaction (in shares) \| shares			930,993
Consideration received on sale of stock			$ 6,055,000
Payments for stock issuance costs			$ (473,000)
At-the-Market Offering, Amendment No. 1 \| Maximum
Subsidiary, Sale of Stock [Line Items]
Sale of stock, aggregate offering price		$ 50,000,000
At-the-Market Offering
Subsidiary, Sale of Stock [Line Items]
Number of shares issued in transaction (in shares) \| shares				3,977,053	4,907,986
Consideration received on sale of stock				$ 18,505,000	$ 24,560,000
Payments for stock issuance costs				$ (933,000)		$ (1,406,000)
Remaining amount available for offering	$ 49,038,000